The content is available as a PDF (365.9 KB).
editorial . 2020 Oct 3:ciaa1508. doi: 10.1093/cid/ciaa1508
Widespread and frequent testing is essential to controlling COVID-19 in the United States
Eli S Rosenberg
1,2,✉, David R Holtgrave
2,3
Eli S Rosenberg
1
Department of Epidemiology and Biostatistics, University at Albany School of Public Health, State University of New York, Rensselaer NY
2
Center for Collaborative HIV Research in Practice and Policy, University at Albany School of Public Health, State University of New York, Rensselaer NY
Find articles by Eli S Rosenberg
David R Holtgrave
2
Center for Collaborative HIV Research in Practice and Policy, University at Albany School of Public Health, State University of New York, Rensselaer NY
3
Department of Health Policy, Management, and Behavior, University at Albany School of Public Health, State University of New York, Rensselaer NY
Find articles by David R Holtgrave
1
Department of Epidemiology and Biostatistics, University at Albany School of Public Health, State University of New York, Rensselaer NY
2
Center for Collaborative HIV Research in Practice and Policy, University at Albany School of Public Health, State University of New York, Rensselaer NY
3
Department of Health Policy, Management, and Behavior, University at Albany School of Public Health, State University of New York, Rensselaer NY
✉
Corresponding Author: Eli Rosenberg, Department of Epidemiology and Biostatistics, University at Albany School of Public Health, 1 University Place, Room 123, Rensselaer, NY 12144, 518-486-9667, erosenberg2@albany.edu
Received 2020 Sep 25.
Keywords: COVID-19, testing, model, cost-effectiveness
© The Author(s) 2020. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.
This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model)
This article is made available via the PMC Open Access Subset for unrestricted re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the COVID-19 pandemic or until permissions are revoked in writing. Upon expiration of these permissions, PMC is granted a perpetual license to make this article available via PMC and Europe PMC, consistent with existing copyright protections.
PMCID: PMC7665340 PMID: 33009802
See "Clinical Impact, Costs, and Cost-effectiveness of Expanded Severe Acute Respiratory Syndrome Coronavirus 2 Testing in Massachusetts" in volume 73 on page e2908.